Day One Biopharmaceuticals, Inc.DAWNEarnings & Financial Report
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.
DAWN Q3 FY2025 Key Financial Metrics
Revenue
$39.8M
Gross Profit
N/A
Operating Profit
$-24.3M
Net Profit
$-19.7M
Gross Margin
N/A
Operating Margin
-60.9%
Net Margin
-49.6%
YoY Growth
-57.6%
EPS
$-0.19
Day One Biopharmaceuticals, Inc. Q3 FY2025 Financial Summary
Day One Biopharmaceuticals, Inc. reported revenue of $39.8M (down 57.6% YoY) for Q3 FY2025, with a net profit of $-19.7M (down 153.3% YoY) (-49.6% margin).
Key Financial Metrics
| Total Revenue | $39.8M |
|---|---|
| Net Profit | $-19.7M |
| Gross Margin | N/A |
| Operating Margin | -60.9% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
Day One Biopharmaceuticals, Inc. Q3 FY2025 revenue of $39.8M breaks down across 2 segments, led by Products at $38.5M (96.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $38.5M | 96.8% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3.3% |
Day One Biopharmaceuticals, Inc. Revenue by Segment — Quarterly Trend
Day One Biopharmaceuticals, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and License Agreement With Ipsen Pharma Sas) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 |
|---|---|---|---|---|
| Products | $38.5M | $33.6M | $30.5M | $20.1M |
| License Agreement With Ipsen Pharma Sas | $1.3M | — | — | — |
Day One Biopharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Day One Biopharmaceuticals, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $39.8M | -57.6% | $-19.7M | -49.6% |
| Q2 FY2025 | $33.9M | +313.9% | $-30.3M | -89.4% |
| Q1 FY2025 | $30.8M | — | $-36.0M | -117.0% |
| Q3 FY2024 | $93.8M | — | $37.0M | 39.5% |
| Q1 FY2024 | $0 | — | $-62.4M | N/A |
| Q3 FY2023 | $0 | — | $-46.1M | N/A |
Income Statement
| Q3 2023 | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $93.8M | $30.8M | $33.9M | $39.8M |
| YoY Growth | N/A | N/A | N/A | N/A | 313.9% | -57.6% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | $414.2M | $326.6M | $600.8M | $534.4M | $519.0M | $513.8M |
| Liabilities | $24.6M | $29.8M | $45.3M | $54.8M | $58.2M | $62.9M |
| Equity | $389.6M | $296.8M | $555.5M | $479.5M | $460.8M | $450.9M |
Cash Flow
| Q3 2023 | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-37.1M | $-49.7M | $50.8M | $-59.0M | $-24.8M | $-5.8M |